Amarin Pharma, Inc., Wins Injunction Against FDA's Off-Label Marketing Ban

Friday, August 21, 2015
By Michael L. Smith, R.R.T., J.D., Board Certified by The Florida Bar in Health Law

    
The U.S. District Court for the Southern District of New York granted a preliminary injunction to Amarin Pharma, Inc. (Amarin), prohibiting the Food and Drug Administration (FDA) from enforcing its off-label marketing ban.  The injunction means that Amarin can engage in truthful marketing of Vascepa even when the marketing is used to promote an off-label use of Vascepa.  


FDA Ban on Off-Labeling Drugs.

Off-label use of drugs is the prescribing of a drug for a purpose other than what has been approved by the FDAPhysicians have always been permitted to prescribe FDA-approved drugs for both the FDA-approved purposes and for other purposes not approved by the FDA.  However, the FDA maintains that when a drug manufacturer is marketing or promoting a drug for an off-label use, the manufacturer and its representative can be held criminally liable for misbranding.  A drug is misbranded when its labeling does not contain adequate directions for its use.  The FDA defines "adequate directions" for use as directions sufficient for a layperson to use the drug safely for its intended purpose.  

Amarin manufactures Vascepa, which has been approved for treatment of adults with severe hypertriglyceridemia (triglyceride levels above 500 mg/dL).  Amarin sought FDA approval to market Vascepa for the treatment of persistently high triglycerides (triglyceride levels between 200 and 499 mg/dL and already on statin therapy), which is an off-label use.  The FDA threatened to prosecute Amarin under its misbranding statute, so Amarin filed suit in federal court.


Promoting Off-Labeled Drugs.


The Court reviewed the decision in United States v. Caronia, 703 F.3d 149 (2d Cir. 2012), and determined, consistent with Caronia, that the First Amendment prohibited the FDA from prosecuting truthful promotional speech as misbranding.  The FDA argued that Caronia, had limited application to the facts of that case.  The Court disagreed, and said Caronia was a categorical decision prohibiting the FDA from prosecuting truthful speech promoting the off-label use of drugs as misbranding.

According to the Court, the First Amendment gives qualified protection to commercial speech and pharmaceutical qualifies as commercial speech.  This decision is another significant ruling on the First Amendment protections for commercial speech, and the constitutional limits on the FDA's enforcement of the Federal Food, Drug and Cosmetic Act.  To read a copy of the Court's opinion in United States vs. Caronia, click here.

    
Comments?

Do you think the FDA should enforce the ban on off-labeled drugs? Please leave any thoughtful comments below.


Contact Health Law Attorneys Experienced in the Representation of Health Professionals and Providers.


The attorneys of The Health Law Firm provide legal representation to physicians, pharmacists, pharmacies, nurses, nurse practitioners, CRNAs, pain management doctors, dentists, psychologists and other health providers in Department of Health (DOH) investigations, Drug Enforcement Administration (DEA) investigations, Food and Drug Administration (FDA) matters, FBI investigations, Medicare investigations, Medicaid investigations and other types of investigations of health professionals and providers.

To contact The Health Law Firm, please call (407) 331-6620 or visit our website at www.TheHealthLawFirm.com.


About the Author:
Michael L. Smith, R.R.T., J.D., is Board Certified by The Florida Bar in Health Law. He is an attorney with The Health Law Firm, which has a national practice. Its main office is in the Orlando, Florida, area. www.TheHealthLawFirm.com The Health Law Firm, 1101 Douglas Ave., Altamonte Springs, FL 32714, Phone: (407) 331-6620.


Sources:

Burton, T. M. (2015, August 8). "FDA Dealt Setback On Off-Label Use." The Wall Street Journal.


KeyWords: Amarin, Vascepa, off label marketing, off label marketing ban, off label use, Food and Drug Administration (FDA), FDA, FDA drug approval, generic drugs, name brand prescriptions, prescriptions, pharmacy, pharmacist, drug manufacturers, pharmaceutical manufacturing, Federal Food, Drug and Cosmetic Act, misbranding, defense attorney, defense lawyer, health attorney, health law attorney, health law, health law firm, The Health Law Firm reviews
                    











"The Health Law Firm" is a registered fictitious business name of George F. Indest III, P.A. - The Health Law Firm, a Florida professional service corporation, since 1999.
Copyright © 1996-2015 The Health Law Firm. All rights reserved.
8/21/2015

Like this blog? Add your public comments:

Items in bold indicate required information.